Second Genome Presents Preclinical Data at Crohn's & Colitis Foundation's® IBD Innovate Conference for Potential First in Class Mucosal Healing Therapeutic SG-5-00455
BRISBANE, Calif., Nov. 18, 2021 /PRNewswire/ -- Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers, presented preclinical data from its mucosal healing program in inflammatory bowel disease (IBD) at the Crohn's & Colitis Foundation's IBD Innovate: Product Development in Crohn's & Colitis® virtual conference held November 18-19, and announced its Corporate Circle membership for a three-year term.